Introduction {#sec1-1}
============

Hypertensive disorders of pregnancy constitute an enigmatic and clinically challenging group of pregnancy complications that are responsible for a substantial burden of illness in both industrialized and less industrialized countries. According to June 2014 meta-analysis by the WHO, hypertensive disorders of pregnancy account for 14% of all maternal deaths.\[[@ref1]\] The incidence of pregnancy-induced hypertension (PIH) ranges from 5% to 15% in India.\[[@ref2][@ref3]\]

Hypertensive disorders of pregnancy included chronic hypertension, gestational hypertension, preeclampsia, chronic hypertension with superimposed preeclampsia, and eclampsia. The exact cause and onset of hypertensive disorder of pregnancy is still unresolved, and several theories have been put forward regarding the etiopathogenesis of PIH. Research is still continuing to identify an ideal marker which can predict the future development of PIH so that these mothers can be grouped as high risk and close monitoring and necessary management can be instituted. Several tests have been proposed to predict hypertension in pregnancy including biochemical and hormonal assay, so that timely intervention may be instituted, but till this day, no single test has achieved that purpose.

In PIH, there is a mid-trimester surge of beta-human chorionic gonadotropin (hCG) level due to the overwhelming secretory response of the immunologically modified trophoblast.\[[@ref4]\] Furthermore, there is a 2--3 times rise in serum triglyceride (TG) concentration which is likely to get accumulated in the uterine spiral arteries contributing to endothelial activation and damage.\[[@ref5]\]

It has been proposed that instead of a single investigation, a combination of antenatal tests could predict the occurrence of PIH with more specificity and sensitivity. With this aim in mind, we considered evaluating maternal beta-hCG levels and lipid profile in the second trimester of pregnancy as predictors of PIH and its time of onset for our study.

Materials and Methods {#sec1-2}
=====================

This hospital-based prospective study was conducted over a period of 1 year at Tata Main Hospital, Jamshedpur, India. The study was approved by the Institutional Ethical Committee. All pregnant women between 13 and 18 weeks of gestation with single uncomplicated pregnancy with systolic blood pressure (BP) \<140 mmHg and diastolic BP \<90 mmHg who were willing to follow up and deliver in our hospital were included in our study. The women included in the study were told about the potential significance of the test and its benefit in detail in their own language, and informed consent was obtained. Women with hypertension diagnosed before 20 weeks of gestation, multiple pregnancy, diabetes mellitus, and history of PIH in previous pregnancy and pregnant women with renal parenchymal disease or with any medical disease which may alter lipid profile, thyroid disease, and congenital anomaly proved with ultrasound were excluded from the study.

All patients were investigated for serum beta-hCG and lipid profile for two occasions, once in the early second trimester (14--18 weeks) and another at the late second trimester (24--28 weeks). Serum beta-hCG level was measured by chemiluminescence immunoassay. Total cholesterol (TC), TG, and high-density lipoprotein (HDL) were evaluated using diagnostic kits, whereas low-density lipoprotein (LDL) and very-low-density lipoprotein (VLDL) were calculated using the Friedewald formula. The values were tabulated and analyzed based on the standard normal values mentioned for their corresponding period of gestation. The patients were followed till delivery to assess whether they developed hypertension at any stage of pregnancy. The final maternal outcome obtained thereafter was also recorded, tabulated, and analyzed.

Statistical analysis {#sec2-1}
--------------------

Data were summarized by routine descriptive studies such as mean, median, standard deviation, and quartiles for numerical variables and counts and percentages for categorical variables. Univariate analysis was done by comparing beta-hCG and individual lipid profile parameters between patients with PIH and those without PIH. Student\'s *t*-test was employed to differentiate between two means, and statistical analysis was done using the Chi-square test. Software used: Statistical version 6 (StatSoft Inc., Tulsa, Oklahoma, USA, 2001), MedCale version 11.6 (MedCalc Software, Mariakerke, Belgium, 2011).

Results {#sec1-3}
=======

Of 200 women, 184 women completed the study, whereas 4 underwent MTP and the rest 12 were lost to follow-up. Of 184 patients followed, 27 women developed PIH constituting 14.67% of the study population. Thus, the incidence of PIH was 14.67% in our study. When further subdivided, the incidence of preeclampsia was 22.22% of the PIH cohort (*n* = 6) \[[Table 1](#T1){ref-type="table"}\]. Of these 6 preeclamptic patients, 3 women had early-onset preeclampsia (onset before 34 weeks), whereas the rest 3 had late-onset disease. Most of the patients (88.88%) had late-onset PIH (after 34 weeks), whereas the incidence of early-onset PIH (before 34 weeks) was only 11.12%. The incidence of PIH was slightly higher in the age group of 25--30 years and lowest in the age group of 20--25 years. In the PIH group, 55.55% of the patients had normal body mass index (BMI), 29.6% were overweight, and 14.8% were obese. We found that the incidence of PIH in a particular population rises with BMI. Of total 184 women, 33 (17.93%) women delivered preterm. About 40.7% had preterm delivery in the PIH group compared to 14.01% in the normotensive group. Sixty-five percent of the total study population underwent LSCS. The incidence of LSCS in the PIH group was 74% in comparison to 63% in case of normotensive patients. Descriptive statistics of the numerical variables of entire study population are shown in [Table 2](#T2){ref-type="table"}. On receiver operating characteristic (ROC) curve analysis, it was found that at a cutoff level of 67750 mIU/ml, beta-hCG at 14--18 weeks can predict PIH with 51.85% sensitivity (95% confidence interval \[CI\] = 31.9--71.3) and 88.54% specificity (95% CI = 82.5--92.1) \[[Figure 1](#F1){ref-type="fig"}\]. Similarly, serum beta-hCG above 23180 mIU/ml at 24--28 weeks can predict PIH/preeclampsia with 62.96% sensitivity (95% CI = 42.4--80.6) and 72.61% specificity (95% CI = 64.9--79.4) \[[Figure 2](#F2){ref-type="fig"}\]. In both the early and late second trimesters, serum cholesterol, TG, and VLDL levels were significantly raised in PIH population compared to the normotensive group (*P* \< 0.05). Serum LDL level is significantly increased in the late second trimester in PIH patients but not in the early second trimester \[[Table 3](#T3){ref-type="table"}\].

###### 

Distribution of pregnancy-induced hypertension cohort into pregnancy-induced hypertension and preeclampsia

  Group              Number of patients   Percentage
  ------------------ -------------------- ----------------------------------
  PIH                21                   77.77
  Preeclampsia       6                    22.22
  Onset \<34 weeks   3                    50 of patients with preeclampsia
  Onset \>34 weeks   3                    50 of patients with preeclampsia

PIH: Pregnancy-induced hypertension

###### 

Descriptive statistics of numerical variables - whole Cohort (*n*=184)

                  Valid *n*   Mean        Median      Minimum     Maximum     Lower quartile   Upper quartile   SD           SE
  --------------- ----------- ----------- ----------- ----------- ----------- ---------------- ---------------- ------------ ----------
  Age             184         24.72       24.50       18.00       35.0        23.00            26.0             3.192        0.235
  BMI             184         23.66       23.35       17.50       32.4        22.20            25.8             3.085        0.227
  Time of onset   27          250.52      253.00      211.00      269.0       247.00           258.0            12.008       2.311
  Beta-hCG1       184         91,723.97   76,520.00   10,800.00   566,400.0   49,400.00        113,420.00       73,221.418   5397.955
  Beta-hCG2       184         22,456.25   12,365.00   2340.00     112,980.0   9670.0           32,155.0         19,908.520   1467.676
  TC1             184         175.65      176.00      146.00      220.0       168.00           181.5            12.113       0.893
  TC2             184         203.97      202.00      162.00      265.0       195.50           213.0            16.482       1.215
  TG1             184         127.36      124.00      105.00      186.00      118.00           133.5            15.290       1.127
  TG2             184         147.28      143.00      118.00      210.0       132.00           152.0            18.914       1.394
  LDL1            184         89.60       86.40       52.40       80.8        79.00            93.3             54.716       4.034
  LDL2            184         106.28      106.00      64.00       159.2       96.80            116.7            15.511       1.143
  VLDL1           184         27.04       24.80       2.00        346.0       23.30            26.5             23.893       1.761
  VLDL2           184         29.45       28.60       22.40       44.0        26.40            30.4             3.852        0.284
  HDL1            184         64.45       65.00       51.00       80.0        58.50            70.0             6.686        0.493
  HDL2            184         68.18       69.00       54.00       87.0        63.00            74.0             6.615        0.488

hCG: Human chorionic gonadotropin; TC: Total cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein; VLDL: Very LDL; HDL: High-density lipoprotein; SD: Standard deviation; SE: Standard error; BMI: Body mass index

![Receiver operating characteristic curve analysis for predicting pregnancy-induced hypertension on the basis of beta-human chorionic gonadotropin 1 (14--18 weeks)](IJABMR-10-49-g001){#F1}

![Receiver operating characteristic curve analysis for predicting pregnancy-induced hypertension on the basis of beta-human chorionic gonadotropin 2 (24--28 weeks)](IJABMR-10-49-g002){#F2}

###### 

Comparison of numerical variables between pregnancy-induced hypertension and nonpregnancy-induced hypertension - Student's unpaired *t*-test

          Mean PIH   Mean non-PIH   *t*        df    *P*     SD PIH   SD non-PIH
  ------- ---------- -------------- ---------- ----- ------- -------- ------------
  Age     25.59      24.57          1.53837    182   0.126   3.608    3.103
  TC1     192.11     172.82         9.23835    182   0.000   12.933   9.450
  TC2     228.04     199.83         10.31157   182   0.000   13.819   13.012
  TG1     154.30     122.73         14.51953   182   0.000   14.631   9.560
  TG2     183.93     140.97         18.35251   182   0.000   12.857   10.939
  LDL1    95.37      88.61          0.59185    182   0.555   15.719   58.857
  LDL2    121.24     103.70         5.91045    182   0.000   15.068   14.104
  VLDL1   42.37      24.40          3.73531    182   0.000   60.745   2.646
  VLDL2   36.86      28.17          17.98615   182   0.000   2.750    2.237
  HDL1    65.19      64.32          0.61655    182   0.538   7.077    6.632
  HDL2    70.48      67.78          1.97318    182   0.050   7.531    6.387

TC: Total cholesterol; TG: Triglyceride; LDL: Low-density lipoprotein; VLDL: Very LDL; HDL: High-density lipoprotein; SD: Standard deviation; PIH: Pregnancy-induced hypertension

Discussion {#sec1-4}
==========

PIH and preeclampsia syndrome remain one of the intriguing topics even in modern-day obstetrics. Even though complications associated with PIH have been observed from ancient times and various treatment modalities have been suggested, till now early prediction remains beyond our reach. Novel investigative tools applicable preferably during early gestation when there is time for therapeutic modification are needed. In this context, we studied the maternal serum beta-hCG and lipid profile in the early second trimester (14--18 weeks) and the late second trimester (24--28 weeks) for prediction of PIH/preeclampsia and its time of onset. One hundred and eighty-four antenatal women carrying singleton pregnancy and fulfilling all inclusion and exclusion criteria were included in our prospective observational study. Two venous samples were collected from each patient for beta-hCG and lipid profile at 14--18 weeks and then at 24--28 weeks. All relevant patient data and investigations were analyzed statistically.

Most of the patients in the study population were in the age group of 20--25 years, comprising about 54.34%. The mean age for the PIH group was 25.6 years, and in case of the normotensive group, it was 24.6 years. These values were analyzed using unpaired *t*- test, and it was found that *P* = 0.126, which was statistically insignificant. Majority of the women who developed PIH were primigravida (about 74%) were in accordance with studies by other authors. Only 26% of the hypertensive women were multipara. Redman suggested that in later pregnancies, there is development of protective immunologic mechanisms against paternal antigens.\[[@ref6]\] In an overview by Zuspan, PIH occurs mainly in primiparous women (85%) who have 4--5 times higher risk than multiparous women.\[[@ref7]\] When the weight-specific incidence of PIH was studied, it was noted that the incidence rises with rising BMI. It is well documented that obese women have a higher incidence of PIH. Ehrentha *et al*.\[[@ref8]\] reported in 2010 that the risk of PIH rises with maternal prepregnancy BMI.

The number of participants who had preterm delivery was 33 which accounts for 17.93%. This is similar to the study done by Slattery and Morrison\[[@ref9]\] where the incidence was found to be 8%--15%. About 40% of the women belonging to the PIH group had preterm delivery compared to 14% in case of the normotensive group. These values were tabulated and analyzed using Fisher\'s exact test two-tailed, and the *P* value was statistically significant. A prospective study done by Ye *et al*.\[[@ref10]\] in China showed that PIH leads to preterm delivery and iatrogenic prematurity caused due to the necessity to terminate pregnancy. The rate of LSCS in the PIH group was found to be 74.07% in comparison to the normotensive group where it was about 63%. Tuffnell *et al*.\[[@ref11]\] and Sibai\[[@ref3]\] reported LSCS rate of 72.4% and 32.4%, respectively. However, the incidence in our institute was higher. Results obtained were analyzed using Chi-square test, and the *P* value was found to be 0.4645 which was statistically insignificant.

From ROC curve analysis, it was found that for an early second-trimester beta-hCG value above 67,750 mIU/ml, sensitivity was 51.85% and specificity was 88.54% with a positive likelihood ratio of 4.52 and a negative likelihood ratio of 0.54. This is similar to findings by Vidyabati *et al*.\[[@ref12]\] in 2010 that second-trimester serum beta-hCG levels increased significantly in those women who developed PIH and it has a predictive value. More recently, a California-based study conducted by Towner *et al*.\[[@ref13]\] and Taché *et al*.\[[@ref14]\] in 2014 showed that adverse pregnancy outcome in terms of PIH/preeclampsia is more in women with elevated values although no specific cutoff values have been mentioned in either study. Davidson *et al*.\[[@ref15]\] in a retrospective case--control study in 2003 noted small but significant elevations in the concentrations of beta-hCG in the second-trimester serum of women who subsequently developed pregnancy-induced hypertension and preeclampsia.

When we compared the mean value of serum TC in the normotensive and PIH groups, we found that for both early and late second-trimester TC estimations, the *P* value was statistically significant (\<0.05). Vidyabati *et al*.\[[@ref12]\] and Yadav *et al*.\[[@ref16]\] have also reported similar findings. However, no significant alteration in TC level could be observed in the third trimester by De *et al*.\[[@ref5]\] When we compared the mean value of serum LDL cholesterol in the normotensive and PIH groups, we noted that there was no statistically significant difference between early trimester LDL cholesterol in the PIH and normotensive groups but *P* \< 0.05 for late second-trimester LDL cholesterol. This finding in our study differed from other studies by Vidyabati *et al*.\[[@ref12]\] and Cekmen *et al*.\[[@ref17]\] but was supported by De *et al*.\[[@ref5]\] We compared the mean value of serum VLDL cholesterol in the normotensive and PIH groups and found that for both early and late second-trimester VLDL c holesterol estimations, the values were higher in PIH patients than the normotensive group, *P* \< 0.05. Similar findings have been reported by Yadav *et al*.,\[[@ref16]\] Vidyabati *et al*.,\[[@ref12]\] and De *et al*.\[[@ref5]\] We also compared the mean value of serum HDL cholesterol in the normotensive and PIH groups. We found that there was a statistically insignificant variation in both the early and late second-trimester values of HDL cholesterol in the PIH and normotensive groups. Vidyabati *et al*.\[[@ref12]\] and Yadav *et al*.\[[@ref16]\] had similar findings. However, other authors like De *et al*.\[[@ref5]\] and Cekmen *et al*.\[[@ref17]\] noted that plasma HDL levels were significantly lower in PIH patients than controls. A meta-analysis done in 2014 by Spracklen *et al*.\[[@ref18]\] also showed that preeclampsia was associated with elevated TC, non-HDL cholesterol, and TG levels and with lower levels of HDL cholesterol in the third trimester.

Since beta-hCG was not normally distributed, its correlation with time of onset of PIH/preeclampsia was analyzed by means of Spearman\'s correlation coefficient. The coefficient rho was 0.0971, whose *P* = 0.6301 and 95% CI for rho was 0.294--0.460, which does not indicate good correlation between early second-trimester beta-hCG and time of onset. Similarly, for late second-trimester beta-hCG, the coefficient rho was −0.0468, whose *P* = 0.8167 and 95% CI for rho was −0.419--0.339, indicating no correlation. Kang *et al*.\[[@ref19]\] conducted a retrospective cohort study on 32 women with preeclampsia and 3044 controls to estimate the combined screening performance of first and early second-trimester serum markers which included beta-hCG, for the development of preeclampsia, and analyze the correlation among marker levels, week of onset, and severity of the disease. They too could not find any correlation between hCG levels and week of onset of disease.

However, Taché *et al*.\[[@ref14]\] in 2014 noted that with high beta-hCG levels, the risk increases, and this was especially true for early-onset severe preeclampsia, indicating the placental dysfunction. In our study, we were unable to demonstrate any correlation between serum levels of different lipids and time of onset of PIH/preeclampsia. This might be owing to very small number (*n* = 27) of PIH patients that we got in our study population.

In previous studies of plasma lipids of preeclamptic women, the distinction between early- and late-onset diseases has not been made. A study done by Clausen *et al*.\[[@ref20]\] reports that hypertriglyceridemic dyslipidemic pattern of nonfasting plasma lipids at 18 weeks of gestation is associated with the increased risk of developing early but not late-onset preeclampsia.

Conclusion {#sec1-5}
==========

Hypertensive disorders in pregnancy are one of the major causes of maternal morbidity and mortality. An ideal predictor of the disease, the application of which could significantly alter the associated morbidity and mortality, remains elusive. Serum beta-hCG may be used as a predictor of PIH, but the sensitivity of the test is low. It might be of help if this test is provided to women who have risk factors for developing PIH. Maternal lipid profile in the second trimester may also be a good, noninvasive, reproducible, and economical test for prediction of PIH.

Finally, as recent literature shows, the time of onset of preeclampsia is now considered to be a surrogate indicator of the disease severity and etiology. Although in this study correlation between serum beta-hCG and lipid profile and time of onset was not demonstrated, more exhaustive research in a larger population is needed.
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